PRESENTATION

Q2 2023 — Presentation

Q2 2023PDF · 29 pages2.3 MB
Merck
Q2 2023 Earnings
August 1, 2023

-- 1 of 29 --

Agenda
2
Strategy and
Business Update
Rob Davis
Chairman and Chief
Executive Officer
Question & Answer
Session
Business/Financial
Results and Outlook
Caroline Litchfield
Chief Financial Officer
Research
Update
Dr. Dean Li
President, Merck
Research Laboratories

-- 2 of 29 --

Forward-looking statement of Merck & Co., Inc.,
Rahway, N.J., USA
3
This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of
the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and
are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary
regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual
results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency
exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health
care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents
attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future
market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the
company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report
on Form 10-K for the year ended December 31, 2022 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).

-- 3 of 29 --

Strategy &
Business Update
Rob Davis
Chairman and Chief Executive Officer

-- 4 of 29 --

Delivered on our key strategic priorities in Q2 2023
5
Advanced the pipeline to meet
patient unmet need
Achieved strong commercial and
financial performance
Executed on strategic business
development to enhance pipeline
Created long-term value for patients
and shareholders

-- 5 of 29 --

2021 	2022 	2023
Strong underlying Q2 performance 1
6
1. Results from continuing operations attributable to Merck & Co., Inc. 2. Excludes Lagevrio sales of $203 million in 2Q23 and $1.2 billion in 2Q22. 3. GAAP LPS (Loss Per Share) of ($2.35). Both 2Q23 GAAP and non-GAAP
LPS reflect a charge of $10.2 billion or $4.02 per share for the acquisition of Prometheus Biosciences, Inc. 4. Not meaningful 5. Merck does not exclude expenses for upfront and milestone payments related to collaborations
and licensing agreements, or charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions from its non-GAAP results. YTD 2023 non-GAAP results include an aggregate $11.6 billion or
$4.53 per share of R&D expenses related to the Prometheus and Imago acquisitions and upfront payment for the license and collaboration agreement with Kelun. Full year 2022 non-GAAP results include $690 million or
$0.22 of such charges. Full year 2021 non-GAAP results include $1.7 billion or $0.65 of such charges. For 2023, outlook does not assume any additional significant potential business development transactions.
$15.0B
+3%
+14% ex-Exchange, ex-LAGEVRIO
2
Q2 Worldwide Sales
($2.06)
N/M4
Includes one-time charge of $4.02
from Prometheus acquisition
Q2 Non-GAAP LPS3
$48.7B
+17%
$5.37
Full Year Sales
Full Year Non-GAAP EPS5
$59.3B
+22%
GUIDANCE RANGE
$58.6B - $59.6B
2021 	2022 	2023
GUIDANCE RANGE
$2.95 - $3.05
$5.37
$7.48

-- 6 of 29 --

Advancing and augmenting our deep pipeline
7
Oncology
• 	Highlighted important data at ASCO:
‒ 	KEYNOTE-671 for neoadjuvant and
adjuvant for the treatment of non-
small cell lung cancer
‒ 	KEYTRUDA in combination with
V940 1, our Individualized
Neoantigen Therapy (INT) for the
treatment of adjuvant melanoma
‒ 	MK-2870 2, our TROP-2 ADC, for
the treatment of non-small cell
lung cancer
Vaccines and Infectious Disease
• 	Announced positive topline results
for V116, our pneumococcal
conjugate vaccine candidate
specifically designed for adults
General Medicine
Cardiometabolic
• 	Completed FDA submission of
sotatercept in PAH based on the
Phase 3 STELLAR trial
• 	Presented Phase 2a data at EASL for
efinopegdutide, our GLP-1 /
glucagon receptor co-agonist, in
NAFLD
Immunology
• 	Completed acquisition of
Prometheus Biosciences
1. In collaboration with Moderna 2. In collaboration with Kelun

-- 7 of 29 --

Putting the patient at the center of everything we do
8
$4.2B
+20%
$3.4B
+31%
$5.3B
+30%
$4.8B
+27%
$3.9B
+16%
$5.8B
+24%
Guided by our purpose to
continue advancing
innovative science and
broadening access to
patients around the world
2022/2023 Impact Report1 forthcoming
1. Formerly called the ESG report

-- 8 of 29 --

Business/Financial
Results and Outlook
Caroline Litchfield
Chief Financial Officer

-- 9 of 29 --

Strong underlying Q2 worldwide sales growth
10
Merck
WORLDWIDE SALES1,2
$15.0B+3% growth
+11% ex-LAGEVRIO3
+14% ex-exchange, ex-LAGEVRIO3
$13.5B
+6% growth
+14% ex-LAGEVRIO3
+17% ex-exchange, ex-LAGEVRIO3
Human Health
$1.5B
-1% growth
+2% ex-exchange
Animal Health
1. Results attributable to Merck & Co., Inc. 2. Worldwide Sales includes Other Revenue. 3. Excludes Lagevrio sales of $203 million in 2Q23 and $1.2 billion in 2Q22.

-- 10 of 29 --

Oncology: KEYTRUDA continues to drive strong growth
11	Growth rates exclude the impact of foreign exchange.
• KEYTRUDA sales of $6.3B increased 21%
year-over-year, driven by uptake in earlier
stage cancers and continued strong global
demand from metastatic indications
– In the U.S., growth of 21% reflects strong
utilization across earlier stage cancers such as
TNBC, as well as certain types of RCC and
melanoma
– Ex-U.S., 22% increase driven by demand in
metastatic RCC and certain types of H&N
cancer, as well as earlier stage cancers,
including high-risk early stage TNBC and RCC
$4.2B
+20%
$3.4B
+31%
$5.3B
+30%
2Q21 	2Q22 	2Q23
$5.3B
+30%
$4.2B
+20%
$6.3B
+21%

-- 11 of 29 --

Oncology: Solid performance across broad portfolio
• Lynparza 1 sales grew 15% driven primarily by
increased demand in certain international
markets
• Lenvima 2 sales grew 6% due to demand in
advanced RCC and endometrial cancer in the
U.S., partially offset by lower sales in China
$248M
+34%	$178M
+62%
$275M
+17%
$181M
+15%
$151M
+57%
$231M
+33%
12	Growth rates exclude the impact of foreign exchange.
1. In collaboration with AstraZeneca 2. In collaboration with Eisai
2Q21 	2Q22 	2Q23
2Q21 	2Q22 	2Q23
$275M
+17%
$248M
+34%
$310M
+15%
$231M
+33%	$181M
+15%
$242M
+6%

-- 12 of 29 --

Vaccines: Exceptional growth driven by GARDASIL
13
• GARDASIL sales of $2.5B increased 53%
year-over-year primarily driven by strong
global demand, particularly in China
– China growth is benefitting from the
expanded indication of GARDASIL 9 to
females ages 9 to 45
• Strong ongoing pediatric launch of
VAXNEUVANCE $1.2B
+78%
$656M
-24%
$1.7B
+40%
2Q21 	2Q22 	2Q23
$1.7B
+40%
$1.2B
+78%
$2.5B
+53%
Growth rates exclude the impact of foreign exchange.

-- 13 of 29 --

Hospital: Strong demand across key products
14
• BRIDION sales of $502M increased 19%
primarily due to greater share among
neuromuscular blockade reversal agents
in the U.S.
• PREVYMIS sales grew 42% driven by
continued strong global demand
$387M
+67%
$224M
-18%
$426M
+15%
2Q21 	2Q22 	2Q23
$426M
+15%
$387M
+67%
$502M
+19%
$93M
+41%$63M
+67%
$103M
+18%
$94M
+20%
$82M
+31%
$129M
+44%
Growth rates exclude the impact of foreign exchange.
2Q21 	2Q22 	2Q23
$103M
+18%
$93M
+41%
$143M
+42%

-- 14 of 29 --

Animal Health: Growth driven by livestock and companion animal
15
• Animal Health sales increased 2% to $1.5B
– Livestock growth of 2% reflects price actions
and increased demand for swine and poultry
products, partially offset by lower demand for
ruminant products due in part to reduced herd
sizes
– Companion Animal growth of 2% reflects price
actions including for BRAVECTO, partially
offset by supply challenges for certain vaccines
$1.5B
+27%
$1.1B
+3%
$1.5B
+5%
2Q21 	2Q22 	2Q23
$1.5B
+5%
$1.5B
+27% $1.5B
+2%
Growth rates exclude the impact of foreign exchange.

-- 15 of 29 --

Q2 2023 non-GAAP financial results summary 1
Q2 2023 	Q2 2022 	Change Change
Ex-FX
Sales 	$15.0 	$14.6 	+3% 	+7%
Non-GAAP Gross Margin 	76.6% 	74.7% 	+1.9pts 	+2.7pts
Non-GAAP Operating
Expenses2 	$15.9 	$5.2 	N/M 	N/M
Non-GAAP Tax Rate3 -18.4% 	13.8% 	-32.2pts 	N/A
Non-GAAP Earnings /
(Loss) Per Share4 	($2.06) 	$1.87 	N/M 	N/M
$ in billions, except LPS/EPS amounts
16
1. Merck is providing certain 2023 and 2022 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business
performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess
performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior
management’s annual compensation is derived in part using a non-GAAP pre-tax income metric. This information should be considered in addition to, but not as a substitute for or superior to,
information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to the earnings release. 2. 2Q23 non-GAAP results include $10.2 billion of
R&D expense or $4.02 of negative impact to EPS, related to the acquisition of Prometheus Biosciences. 3. Q2 2023 provision for Taxes on Income was $810 million. A pre-tax loss was recorded this
quarter due to the Prometheus one-time charge, which was not tax deductible. As a result, the tax rate was negative in the quarter. 4. Q2 2023 GAAP LPS of ($2.35).

-- 16 of 29 --

Merck updated full-year 2023 guidance
1. Includes an aggregate $11.6 billion of R&D expenses related to the Prometheus and Imago acquisitions and upfront payment for the license and collaboration agreement with Kelun. Outlook does not
assume any additional significant potential business development transactions. 2. Includes $4.53 of one-time charges related to the Prometheus and Imago acquisitions and upfront payment to Kelun. 	17
Prior Guidance 	Updated Guidance 	Key Assumptions
Revenue $57.7B to $58.9B
-3% to -1% (-1% to +1% ex-FX)
$58.6B to $59.6B
-1% to +1% (+1% to +3% ex-FX)
• 	Includes approximately $1B of LAGEVRIO revenue
• 	Ex-LAGEVRIO, growth of 8% to 9% (10 to 11% ex-FX)
• 	Assumes 2 ppt FX headwind
Non-GAAP
Gross Margin Rate ~77.0% 	~77.0%
Non-GAAP
Operating Expenses1 	$23.3B to $24.1B 	$34.0B to $34.6B
• 	Includes additional $10.2B related to upfront charge for
the acquisition of Prometheus and investment to advance
the acquired assets
Other (Income) / Expense 	~$250M of income 	~$100M of expense • 	Includes financing costs related to the acquisition of
Prometheus
Tax Rate 	~17.0% to 18.0% 	~30.5% to 31.5% • 	Includes ~15 ppt negative impact from the acquisition of
Prometheus
Shares Outstanding 	~2.55B 	~2.55B 	• 	Assumes modest share repurchase
Non-GAAP EPS2 	$6.88 to $7.00 	$2.95 to $3.05
• 	Includes $4.02 one-time charge for the Prometheus
acquisition and an additional $0.14 to advance the assets
and finance the transaction
• 	Assumes 5 ppt FX headwind (additional $0.02 headwind)

-- 17 of 29 --

Key modeling considerations
KEYTRUDA
GARDASIL
• 	Anticipate strong year-over-year growth, but not quite at the
levels experienced in recent quarters
• 	Continue to expect strong volume growth to be partially offset
by pricing headwinds, particularly in key European markets
• 	In the second quarter, there was a small benefit from wholesaler
purchase timing in the U.S. which is expected to reverse in the
third quarter
18
• 	Expect the pace of full year growth to be higher in 2023 relative
to 2022, with first half growth above that of the second half due
in part to the timing of shipments in China

-- 18 of 29 --

19
Continue to invest in our
pipeline and business while
augmenting our pipeline
with value enhancing
business development
$2.6
$1.0 $1.9
$10.9
$0.3
After-Tax R&D 	CapEx 	Dividends
Paid
Business
Development
(ex-divestitures)
Share Repurchase
$ Billions1
1. Reflects Q2 spend. 2. Includes payment for the Prometheus acquisition.
Remain committed to balanced capital allocation strategy
Capital allocation order of priority
2

-- 19 of 29 --

Research Update
Dr. Dean Li
President, Merck Research Laboratories

-- 20 of 29 --

Driving value for patients and shareholders by progressing our pipeline
21
Key regulatory milestones
since the last earnings call:
Key data & clinical advancements
since the last earnings call:
• 	In the U.S., the FDA:
o Granted approval of Lynparza1 in combination with abiraterone and
prednisone in patients with deleterious or suspected deleterious BRCAm
metastatic castration-resistant prostate cancer
o Accepted sBLA for KEYTRUDA in combination with chemotherapy in
patients with locally advanced unresectable or metastatic biliary tract cancer
o Approved a new indication for PREVYMIS for prophylaxis of cytomegalovirus
(CMV) disease in adult kidney transplant recipients at high risk
o Accepted the re-submission of NDA for gefapixant in patients with refractory
or unexplained chronic cough
• 	In the EU, the EMA:
o Accepted sMAA for KEYTRUDA in combination with trastuzumab and
chemotherapy in patients with locally advanced unresectable or metastatic
HER2- positive gastric or gastroesophageal junction adenocarcinoma
o Received positive CHMP opinion for gefapixant in patients with refractory or
unexplained chronic cough
• 	In Japan, the PMDA:
o Granted approval of KEYTRUDA in patients with relapsed or refractory
primary mediastinal B-cell lymphoma
o Accepted sJNDA for KEYTRUDA in combination with chemotherapy in 1L
treatment of locally advanced unresectable or metastatic gastric or
gastroesophageal junction adenocarcinoma, as well as in patients with locally
advanced unresectable or metastatic biliary tract cancer
o Granted approval of VAXNEUVANCE in pediatrics
• 	In China, the CDE:
o Granted approval of Koselugo1 for the treatment of symptomatic, inoperable
plexiform neurofibromas in pediatric patients with neurofibromatosis type I
ages 3 years and older
1. In collaboration with AstraZeneca 2. In collaboration with Eisai 3. In collaboration with Moderna 4. In collaboration with Kelun
• 	Presented data across broad oncology portfolio at ASCO, including for
KEYTRUDA (KN-671, KN-483, KN-581, KN-716, KN-826), Lenvima2, Lynparza1,
WELIREG, mRNA-4157/V9403 (INT) and MK-2870/SKB2644 (TROP2 ADC)
• 	Announced positive topline results for KN-811 evaluating KEYTRUDA in
combination with trastuzumab as 1L treatment in patients with HER2-positive
advanced gastric or gastroesophageal junction adenocarcinoma in PD-L1 positive
patients
• 	Announced Phase 3 KN-A18 trial met primary endpoint of progression-free
survival in patients with newly diagnosed high-risk locally advanced cervical
cancer
• 	Announced Phase 3 KN-756 trial met one of its dual primary endpoints of
pathological complete response rate in patients with high-risk, early-stage
ER+/HER2- breast cancer
• 	Presented Phase 2a data at EASL for efinopegdutide (MK-6024), an
investigational GLP-1/glucagon receptor co-agonist, in patients with nonalcoholic
fatty liver disease (NAFLD), which has advanced to Phase 2b in nonalcoholic
steatohepatitis (NASH)
• 	Completed BLA submission of sotatercept for pulmonary arterial hypertension
(PAH) to the FDA
• 	Announced positive topline results from two Phase 3 trials evaluating V116 in
vaccine-naïve and previously vaccinated individuals

-- 21 of 29 --

Clinical progress 	Regulatory updates
• 	KEYNOTE-756: Phase 3 trial met one of its dual primary endpoints of pCR
for treatment of patients with high-risk early-stage ER+/HER2- breast
cancer
• 	KEYNOTE-A18: Phase 3 trial met one of its primary endpoints of PFS for
treatment of patients with high-risk locally advanced cervical cancer
• 	Promising data presented at ASCO:
‒ 	KEYNOTE-671: KEYTRUDA perioperative regimen reduced risk of
disease recurrence, progression, or death by 42% in patients with
resectable stage II, IIIA or IIIB NSCLC
‒ 	KEYNOTE-942: V9401 (INT) and KEYTRUDA reduced risk of distant
metastasis or death by 65% in patients with stage III/IV melanoma
following complete resection
‒ Initiated Phase 3 trial for adjuvant treatment of high risk, stage II to IV melanoma
‒ 	MK-2870 2: Showed encouraging anti-tumor activity in patients with
locally advanced or metastatic NSCLC
• 	PROpel: received FDA approval for Lynparza 3 in combination with
abiraterone and prednisone in patients with deleterious or suspected
deleterious BRCA-mutated mCRPC
• 	KEYNOTE-966: sBLA for KEYTRUDA in combination with chemotherapy in
patients with locally advanced unresectable or metastatic biliary tract
cancer accepted for FDA review
• 	KEYNOTE-811:
‒ 	KEYTRUDA in combination with trastuzumab and chemotherapy
showed significant improvement in PFS in 1L treatment of HER2-
positive advanced gastric or GEJ adenocarcinoma in patients whose
tumors were PD-L1 positive
‒ 	Received positive EMA opinion
22
Continuing to advance our broader oncology program
1. In collaboration with Moderna 2. In collaboration with Kelun 3. In collaboration with AstraZeneca

-- 22 of 29 --

Vaccines and Infectious Disease 	General Medicine
23
Progressing our broader pipeline
1. Centers for Disease Control and Prevention, IPD serotype data 2019, as compiled from data provided through Active Bacterial Coresurveillance (ABCs).
CARDIOMETABOLIC
 
• 	Completed FDA submission of sotatercept for the
treatment of adults with PAH based on the Phase 3
STELLAR trial
• 	Presented positive data at EASL from the Phase 2a trial
evaluating efinopegdutide, our investigational GLP-1 /
glucagon receptor co-agonist, in patients with NAFLD
and initiated Phase 2b trial in pre-cirrhotic NASH
COUGH
• 	FDA accepted re-submission of the NDA for gefapixant
in patients with refractory or unexplained chronic cough
VACCINES
• 	V116, our investigational pneumococcal conjugate
vaccine specifically designed for adults:
‒protects against serotypes that are responsible for ~85% of
invasive pneumococcal disease in adults ages ≥65 1
‒includes 8 serotypes that are currently not covered by
approved vaccines, and are responsible for ~30% of invasive
pneumococcal disease in adults ages ≥65 1
• 	Announced positive topline data for V116 for two Phase 3
trials (STRIDE-3 and STRIDE-6)
ID 	• 	Received FDA approval for PREVYMIS for prophylaxis of
CMV disease for adult recipients of kidney transplant
who are at high-risk of infection

-- 23 of 29 --

Accelerating our presence in immunology
24
• 	Focused expertise in
immunology
• 	Deep genetic and biological
insights from Prometheus
360 Data Science Platform
• 	Risk-stratified biomarker
approach
• 	Suite of immunology
pipeline compounds
• 	Deep expertise in clinical
trial design and execution
• 	Global clinical trial scale
• 	Proven track record of
developing and
implementing precision
medicine strategies
• 	Emerging immunology
discovery pipeline
+

-- 24 of 29 --

Q&A
Rob Davis
Chairman & Chief Executive Officer
Caroline Litchfield
Chief Financial Officer
Dr. Dean Li
President, Merck Research Laboratories
Peter Dannenbaum
Vice President, Investor Relations

-- 25 of 29 --

Appendix
26

-- 26 of 29 --

Q2 2023 GAAP financial results summary
27
Q2 20231 Q2 2022 	Change 	Change Ex-FX
Sales 	$15.0 	$14.6 	+3% 	+7%
Operating Expenses 	$16.0 	$5.3 	N/M 	N/M
Tax Rate 	-11.9% 	12.0% 	-23.9pts 	N/A
GAAP Earnings /
(Loss) per Share ($2.35) 	$1.55 	N/M 	N/M
$ in billions, except LPS/EPS amounts
1. 2Q23 GAAP results include $10.2 billion or $4.02 of such charges related to the acquisition of Prometheus Biosciences.

-- 27 of 29 --

$10.4
$4.2
$7.2
$13.8
$0.5
$0
$3
$6
$9
$12
$15
After-Tax R&D 	CapEx 	Dividends Paid 	Business
Development
(ex-divestitures)
Share
Repurchase
Capital allocation: Trailing twelve months
~$15B
Over 5 years, including expanding
manufacturing capacity for Oncology, Vaccines,
and Animal Health. Includes >$10B in the U.S.
Billions
$1.76 	$1.80 	$1.84 	$1.88 	$1.92
$2.20
$2.44
$2.60
$2.76
$2.92
$1.40
$1.70
$2.00
$2.30
$2.60
$2.90
$3.20
2014 	2015 	2016 	2017 	2018 	2019 	2020 	2021 	2022 	2023
Dollars per share	
+2% 	+2% 	+2% +2% 	+2%
+11%
+15%
+7%
Over the past 12 months
Capital investments
2023 to 2027
Commitment to the dividend
28
Well positioned balance sheet
with capacity to fund
additional value-enhancing
business development
opportunities
+6%
Order of priority
+6%
E
1. Includes payments reflected in operating cash flow
1

-- 28 of 29 --

Phase 2 	Phase 3 	Under regulatory review
Oncology
V181
Dengue Virus
Vaccines
Infectious diseases
MK-8189 4
Schizophrenia
Neuroscience
Gefapixant (MK-7264)
Cough (US, EU)
General medicine
General medicine
As of August 2, 2023
Infectious diseases
Oncology 	Oncology
MK-1942
Treatment Resistant Depression
MK-6024 (efinopegdutide)
NASH
MK-8591B (islatravir+MK-8507) 1
HIV-1 Infection
MK-8591D (islatravir+lenacapavir) 2
HIV-1 Infection
KEYTRUDA (MK-3475)
CSCC (EU)
Hepatocellular (EU)
Mesothelioma
Ovarian
SCLC
MK-1026 (nemtabrutinib)
Hematological Malignancies
MK-1308A (quavonlimab
+pembrolizumab)
RCC
MK-7684A (vibostolimab
+pembrolizumab)
Melanoma
NSCLC
SCLC
MK-4280A (favezelimab
+pembrolizumab)
CRC
Hematological Malignancies
LENVIMA (MK-7902)
Esophageal
Gastric
HNSCC
NSCLC
LYNPARZA (MK-7339)
NSCLC
SCLC
WELIREG (MK-6482)
RCC
TUKYSA (MK-7119)
Breast
CRC
MK-3475A
(pembrolizumab
+hyaluronidase)
NSCLC
V940
Melanoma
MK-8591A (doravirine+islatravir) 2
HIV-1 Infection
LAGEVRIO (MK-4482) 3
COVID-19 antiviral
KEYTRUDA (MK-3475)
2L HCC (US)
LA Merkel Cell (US)
Adjuvant NSCLC (EU)
HER2+ Gastric (EU)
Resectable NSCLC (US, EU)
1L HER2- Gastric (US, EU, JPN)
1L Biliary (US, EU, JPN)
LYNPARZA (MK-7339)
Metastatic 1L Prostate (JPN)
MK-0616
Hypercholesterolemia
MK-2060
Thrombosis
MK-5475
Pulmonary Arterial Hypertension
MK-7962 (sotatercept)
Pulmonary Hypertension due to Left
Heart Disease
Cardiovascular
MK-4830
CRC
Esophageal
Melanoma
NSCLC
Ovarian
RCC
SCLC
MK-5684
Prostate
MK-5890 (boserolimab)
NSCLC
SCLC
LYNPARZA (MK-7339)
Advanced Solid Tumors
LENVIMA (MK-7902)
Biliary
Pancreas
Prostate
MK-2870
Neoplasm Malignant
KEYTRUDA (MK-3475)
Advanced Solid Tumors
Prostate
MK-3543
(bomedemstat)
Myeloproliferative
Disorders
MK-4280
(favezelimab)
NSCLC
MK-4280A
(favezelimab+pembroli
zumab)
Bladder
Esophageal
Melanoma
RCC
SCLC
WELIREG (MK-6482)
Biliary
Certain VHL tumors (EU)
CRC
Endometrial
Esophageal
HCC
Pancreatic
Rare Cancers
TUKYSA (MK-7119)
Advanced Solid Tumors
Bladder
Biliary
Cervical
Endometrial
Gastric
NSCLC
SCLC
MK-7684A
(vibostolimab
+pembrolizumab)
Biliary
Bladder
Breast
Cervical
CRC
Endometrial
Esophageal
Gastric
HCC
HNSCC
Hematological Malignancies
Ovarian
Prostate
MK-0482
NSCLC
MK-1308 (quavonlimab)
NSCLC
MK-1308A
(quavonlimab
+pembrolizumab)
CRC
HCC
Melanoma
SCLC
MK-2140 (zilovertamab
vedotin)
Bladder
Breast
Gastric
Hematological Malignancies
NSCLC
Ovarian
Pancreas
Broad and innovative pipeline to solve significant unmet medical needs
29
Vaccines
MK-1654 (clesrovimab)
Respiratory Syncytial
Virus (RSV)
1 On FDA clinical hold 2On FDA partial clinical hold for higher doses than those used in current clinical trials	
3 Available in the US under EUA 4 Development is co-funded by Royalty Pharma	
5 Requested re-examination of EU MAA following CHMP major objection of data to support market authorization
MK-7962 (sotatercept)
Pulmonary Arterial Hypertension
Cardiovascular
V116
Pneumococcal vaccine,
adult
MK-7240
Ulcerative Colitis
Immunology

-- 29 of 29 --